• Regeneron Pharmaceuticals triggered a payment upon reaching a development milestone with its Chinese collaborator, JW Therapeutics.
  • This advances the first clinical application of Medigene’s End-to-End Platform for creating potentially best-in-class TCRs.

Planegg/Martinsried, December 3, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), a cancer-focused immuno-oncology company developing T cell receptor (TCR)-guided therapies, today announced receipt of a USD $1 million milestone payment from Regeneron Pharmaceuticals, Inc. This payment resulted from a development milestone achieved in a China-based trial. Regeneron acquired the MAGE-A4-TCR program through its April 2024 purchase of 2seventy bio Inc.’s oncology and autoimmune cell therapy pipeline. The milestone relates to Regeneron’s MAGE-A4 cell therapy, which uses a Medigene-developed T cell receptor (TCR) targeting MAGE-A4, and is being tested by JW Therapeutics (a former 2seventy bio, Inc. collaborator).

“We are pleased with this program’s progress, bringing our MAGE-A4-directed TCR into clinical trials and potentially providing initial clinical validation of our unique TCR discovery and generation capabilities and our End-to-End Platform technologies,” stated Dr. Selwyn Ho, Medigene’s Chief Executive Officer. “We anticipate the trial results and remain dedicated to providing superior, distinct T cell receptors for various TCR-guided therapies treating solid tumor cancers.”

This payment aligns with the Company’s current financial projections; therefore, this milestone confirmation does not alter 2024 guidance.

— end of press release —

About Medigene AG
Medigene AG (FSE: MDG1) is an immuno-oncology platform company committed to developing effective T cell receptor (TCR)-guided cancer therapies. Its End-to-End Platform produces optimal 3S (sensitive, specific and safe) T cell receptors with unique properties applicable to various treatment methods, including off-the-shelf TCR-guided T cell engager (TCR-TCE) therapies (MDG3010), TCR-natural killer cell (TCR-NK) therapies, and T cell receptor engineered T cell (TCR-T) therapies (MDG1015). For more information, please visit

This press release includes forward-looking statements reflecting Medigene’s current views. Medigene’s actual results may differ substantially from these forward-looking statements. Medigene is not obligated to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Medigene AG
Pamela Keck
Phone: +49 89 2000 3333 01
Email:

To unsubscribe from Medigene communications, please email investor@medigene.com. We will then remove your address from our distribution list.